Letters to the Editor

The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology

Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam
Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam
Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands; HOVON Foundation, Rotterdam
Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands; HOVON Foundation, Rotterdam
Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands; HOVON Foundation, Rotterdam
Department of Hematology, Rigshospitalet, Copenhagen
Department of Hematology, HagaZiekenhuis, Den Haag
HOVON Foundation, Rotterdam
European Myeloma Network, EMN
European Myeloma Network, EMN
Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam
Department of Hematology, Radboud UMC, Nijmegen
Amsterdam UMC, location VUMC, Cancer Center Amsterdam
Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway; and
Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam
Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam
Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam
Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam
Haematologica Early view Oct 2, 2025 https://doi.org/10.3324/haematol.2025.288675